Meta-analyses have followed some of the most important advances in the treatment of early-stage Hodgkin lymphoma (HL). In this review, details on all meta-analyses of patients with early-stage HL are discussed. In 1990, the first meta-analysis addressing patients with early-stage HL compared radiotherapy alone to combined-modality treatment (CMT). It was followed in 1998 by an individual-patient meta-analysis examining the role of radiotherapy with and without chemotherapy. In 2006, a comprehensive meta-analysis focusing on the risk of secondary malignancies, including most of the treatment regimens analyzed in clinical trials, was issued. The final analysis was published 2010 and provides important information for the ongoing discussion concerning the role of CMT compared to chemotherapy alone and is therefore discussed in more detail. In addition, the methodology and reporting of meta-analyses have improved over time.

Keywords:
Chemoradiotherapy, Chemotherapy, Combined-modality treatment, Early-stage lymphoma, Hodgkin lymphoma, Radiotherapy
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.